Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$1.39B+78.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brenton L. Saunders
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,000
- Beta
- 0.56
- Country
- CA
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.94
Financials
Revenue
$1.39B+79.0%Net Income
$-14.00M-126.4%EBITDA
$184.00M+30.0%Free Cash Flow
$82.00M+124.7%EPS (diluted)
$-0.04-126.0%Shares Outstanding (diluted)
357.10M+2.0%Operating Expenses
$702.00MCash & Debt
$367.00MReturn of Capital
$27.00MRevenue by Segment (annual)
$5.10BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.10B | $-360.00M | $-1.02 |
| 2024 | $4.79B | $-317.00M | $-0.90 |
| 2023 | $4.15B | $-260.00M | $-0.74 |
| 2022 | $3.77B | $6.00M | $0.04 |
| 2021 | $3.77B | $182.00M | $0.52 |
| 2020 | $3.41B | $-18.00M | $-0.05 |
| 2019 | $3.78B | $298.00M | $0.85 |
| 2018 | $3.67B | $710.00M | $2.03 |
Valuation
BLCOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (5)
- Newsbusinesswire.com·3d ago·Neutral
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor …
View source ↗ - Newszacks.com·24d ago·Positive
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
View source ↗ - Newsbusinesswire.com·28d ago·Neutral
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company's next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for prem…
View source ↗ - Newsseekingalpha.com·44d ago·Positive
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
View source ↗ - Newsmarketbeat.com·45d ago·Negative
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.21 per share
Typical surprise +4.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.16 vs $0.15beat
- Wed, Apr 29$0.08 vs $0.06beat
- Wed, Feb 18$0.32 vs $0.35miss
- Wed, Oct 29$0.18 vs $0.16beat
- Wed, Jul 30$0.07 vs $0.06beat
- Wed, Apr 30$-0.07 vs $0.03miss
Estimates and results for BLCO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLCO officers and directors.
- Bought
- $1.2m
- Sold
- $1.2m
9 trades
3 trades
- Munsch Fredericksold
- Von Eschenbach Andrew C.sold
- Von Eschenbach Andrew C.sold
- Bailey A Robert Dbought
- Eldessouky Sambought
- Saunders Brent Lbought
- Ross Thomas W. Sr.bought
- Alfonso Eduardobought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BLCO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.